Design of a Compact Indirect Slot-Fed Wideband Patch Array with an Air SIW Cavity for a High Directivity in Missile Seeker Applications

This research proposes a compact indirect slot-fed wideband patch array antenna for a missile seeker application. The proposed single antenna consists of three dielectric layers for a radiator, an air substrate-integrated waveguide (SIW) cavity, and an indirect feeding network. The rectangular patch is used as a radiator on the first substrate layer, and the air SIW cavity (ASIWC) is employed to obtain high directivity and low mutual coupling characteristics in the second substrate layer. In the third layer, an indirect feeding structure is used to achieve the wideband characteristics in the Ka-band. The single element is extended to a 4 x 1 linear array with fabrication, and the fabricated array characteristics are measured in a full anechoic chamber. The measured operating fractional frequency bandwidth is 9.2%, and the measured array gain is 11.7 dBi at the bore-sight direction (theta(0) = 0 degrees)

Long-term survival benefits of intrathecal autologous bone marrow-derived mesenchymal stem cells (Neuronata-R®: lenzumestrocel) treatment in ALS: Propensity-score-matched control, surveillance study

ObjectiveNeuronata-R® (lenzumestrocel) is an autologous bone marrow-derived mesenchymal stem cell (BM-MSC) product, which was conditionally approved by the Korean Ministry of Food and Drug Safety (KMFDS, Republic of Korea) in 2013 for the treatment of amyotrophic lateral sclerosis (ALS). In the present study, we aimed to investigate the long-term survival benefits of treatment with intrathecal lenzumestrocel.MethodsA total of 157 participants who received lenzumestrocel and whose symptom duration was less than 2 years were included in the analysis (BM-MSC group). The survival data of placebo participants from the Pooled-Resource Open-Access ALS Clinical Trials (PROACT) database were used as the external control, and propensity score matching (PSM) was used to reduce confounding biases in baseline characteristics. Adverse events were recorded during the entire follow-up period after the first treatment.ResultsSurvival probability was significantly higher in the BM-MSC group compared to the external control group from the PROACT database (log-rank, p < 0.001). Multivariate Cox proportional hazard analysis showed a significantly lower hazard ratio for death in the BM-MSC group and indicated that multiple injections were more effective. Additionally, there were no serious adverse drug reactions found during the safety assessment, lasting a year after the first administration.ConclusionThe results of the present study showed that lenzumestrocel treatment had a long-term survival benefit in real-world ALS patients

Data_Sheet_2_Long-term survival benefits of intrathecal autologous bone marrow-derived mesenchymal stem cells (Neuronata-R®: lenzumestrocel) treatment in ALS: Propensity-score-matched control, surveillance study.docx

ObjectiveNeuronata-R® (lenzumestrocel) is an autologous bone marrow-derived mesenchymal stem cell (BM-MSC) product, which was conditionally approved by the Korean Ministry of Food and Drug Safety (KMFDS, Republic of Korea) in 2013 for the treatment of amyotrophic lateral sclerosis (ALS). In the present study, we aimed to investigate the long-term survival benefits of treatment with intrathecal lenzumestrocel.MethodsA total of 157 participants who received lenzumestrocel and whose symptom duration was less than 2 years were included in the analysis (BM-MSC group). The survival data of placebo participants from the Pooled-Resource Open-Access ALS Clinical Trials (PROACT) database were used as the external control, and propensity score matching (PSM) was used to reduce confounding biases in baseline characteristics. Adverse events were recorded during the entire follow-up period after the first treatment.ResultsSurvival probability was significantly higher in the BM-MSC group compared to the external control group from the PROACT database (log-rank, p ConclusionThe results of the present study showed that lenzumestrocel treatment had a long-term survival benefit in real-world ALS patients.</p